The global biopharmaceutical company Shire has received approval from the FDA to begin selling INTUNIV", an extended release tablet that is used to treat ADHD in people ages 6 to 17 years old.

Once-daily INTUNIV is expected to be available in US pharmacies in November and will come in four dosage strengths (1mg, 2mg, 3mg, and 4mg).

INTUNIV will be marketed in the United States by the existing Shire ADHD sales team of nearly 600 representatives. INTUNIV is not a controlled substance and has no known potential for abuse or dependence. (Source: News-Medical.net)

The efficacy of INTUNIV was established in two separate, placebo-controlled, double-blind clinical trials in children ages 6 to 17 years. In both trials, significant reductions of ADHD symptoms were demonstrated in the patients taking INTUNIV. Improvements became statistically significant one to two weeks after INTUNIV was administered.

Labels: medications, FDA

Posted By: Aspen/CRC 0 Comments

The Center for Science in the Public Interest filed a class action lawsuit against Coca-Cola Co. for falsely advertising its new VitaminWater beverages as healthful drinks.

"VitaminWater is Coke's attempt to dress up soda in a white physician's coat," said the group's litigation director, Steve Gardner. "Underneath it is still sugar water - sugar water that costs ten bucks a gallon."

Coca-Cola promotes VitaminWater as a product that reduces the risk of disease, improves immune function and promotes healthy joints.

Labels: FDA, healthy_foods

Posted By: Aspen Education Group 2 Comments